Current Report Filing (8-k)
February 24 2017 - 5:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 24, 2017 (February 24, 2017)
Transgenomic, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
|
001-36439
|
|
91-1789357
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
12325 Emmet Street, Omaha, NE 68164
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including
area code:
(402) 452-5400
N/A
(Former Name, or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 4.01.
|
Changes in Registrant's Certifying Accountant.
|
Effective as of February 24, 2017, Transgenomic, Inc. (the “Company”),
as approved by the Audit Committee of the Board of Directors (the “Board”), engaged Marcum LLP (“Marcum”)
as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements
for its fiscal year ended December 31, 2016.
During the Company’s two most recent fiscal years ended
December 31, 2014 and December 31, 2015 and in the subsequent interim period through February 24, 2017, neither the Company nor
anyone on its behalf consulted Marcum regarding either: (i) the application of accounting principles to a specified transaction,
either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements,
in connection with which either a written report or oral advice was provided to the Company that Marcum concluded was an important
factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any
matter that was either the subject of a disagreement or reportable event as defined in Regulation S-K, Item 304(a)(1)(iv) and Item
304(a)(1)(v), respectively.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Transgenomic, Inc.
|
|
|
|
|
|
|
|
|
|
Date: February 24, 2017
|
By:
|
/s/ Paul Kinnon
|
|
|
|
Paul Kinnon
|
|
|
|
President and Chief Executive Officer
|
|
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024